Added Value of Automated Electrical Source Localization (EPILOG PreOp®) to Presurgical Evaluation of Refractory Epilepsy
NCT ID: NCT03882151
Last Updated: 2019-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2019-01-15
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Localizing the Epileptogenic Zone With High Resolution Electroencephalography
NCT01090934
Study on Neurocognitive Plasticity in Patients With Focal and Drug-resistant Epilepsy
NCT03543267
National Study on the Interest of EEG-fMRI in the Presurgical Evaluation of Partial Epilepsies Drug
NCT03278210
MEG Versus EEG HR for the Localization of the Epileptogenic Zone as Part of the Pre-surgical Assessment of Epilepsy
NCT03893916
Cortical Excitability Assessment Using Paired Pulses
NCT02245061
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Will be included prospectively the first thirty patients with refractory focal epilepsy being evaluated at CUSL or CHNWL between for surgery, and for whom the cerebral MRI 3 Tesla (3T) did not show any obvious causal lesion.
The pre-surgical evaluation includes (standard of care - SOC):
* EEG-video scalp monitoring (SOC)
* MRI 3Tesla (SOC)
* PET scan FDG (SOC)
* neuropsychological assessment (SOC) MRI examination will be reviewed by an experienced neuroradiologist at CUSL (SOC).
The automated EEG analysis and electrical source localization with EPILOG PreOp® (non-SOC) will be carried out by Epilog (Epilog, Ghent, Belgium), blind to the rest of the workup. The costs of this analysis are 250 € / patient and will be covered by a clinical research fund. If the patient is referred by the CUSL, the costs are charged to account 830 E. If the patient is referred by the CHNWL, the costs are charged to a local scientific account.
The results of the pre-surgical evaluation will be discussed in a multidisciplinary meeting, blind to the results of EPILOG PreOp®, in order to determine the presumed localization of the epileptogenic zone as well as the management plan. The result of this discussion will be classified as follows:
* A focal surgical resection is possible;
* B the assessment must be completed by an invasive EEG (SOC);
* C the option of resective surgery is rejected. If an invasive EEG is considered, the anatomical location of electrodes is planned. Then, the results of EPILOG PreOp® are presented (by Dr. Susana Ferrao Santos) and their influence on the management is evaluated. The possible change of care in relation to the initial plan is considered to be relevant if the EPILOG PreOp® analysis results in
1. a modification of the therapeutic decision as defined above,
2. a modification of the invasive EEG implantation plan or
3. the use of an additional non-invasive imaging method to delineate the epileptogenic zone or to establish the functional risk.
Patients will then be followed for 6 months to determine the clinical relevance of any management changes derived from the EPILOG PreOp® analysis. We will also evaluate the relationship between the localization of the EPILOG + regions (ie the brain regions involved in the irritative zone according to the results provided by the EPILOG PreOp® analysis), the surgical resection, the pathology analysis results and post-surgical results.
EPILOG PreOp® analysis will be carried out using the full length EEG recording collected during video-EEG monitoring (SOC) at CUSL or CHNWL, ie 7 days of recording. with 19-27 electrodes placed according to the international 10-20 system. The EEG data will be transmitted after acquisition and anonymization. For patients investigated at CHNWL, a high-density (non-SOC) recording with 64-76 electrodes will be offered for 24 to 48 hours if the investigator deems it necessary. The additional costs associated with high density EEG are borne by the CHNWL. The result will also be sent to Epilog for analysis, after anonymisation of the data.
The EPILOG PreOp® analysis will begin with automated detection of interictal epileptiform activity using the Persyst program (Persyst Spike Detector P13, Persyst, San Diego, CA, USA), and interictal activity will be clustered and localized. source will be estimated using the sLORETA inverse solution model, using the methodology described previously.
Pathology For all patients undergoing resective surgery, histological sections will be reviewed (SOC). Focal cortical dysplasias will be classified according to the ILAE (SOC) classification. Non-contributory results include: gliosis, absence of microscopic or histological abnormality.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Epilog Preop
patients receive Epilog preop analysis
electrical source imaging
automated analysis of surface EEG with electrocal source imaging
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
electrical source imaging
automated analysis of surface EEG with electrocal source imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* non lesional 3Tesla MRI scan
* epileptic seizure(s) recorded during video-EEG monitoring
Exclusion Criteria
* patient has an obvious causal lesion on MRI scan
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint-Luc University Hospital
Brussels, , Belgium
Centre Hospitalier William Lennox
Ottignies, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018/26SEP/355
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.